{"id":"atorvastatin-calcium-20mg-qd","safety":{"commonSideEffects":[{"rate":"2-3","effect":"Myalgia (muscle pain)"},{"rate":"1-3","effect":"Elevated liver transaminases"},{"rate":"2-5","effect":"Headache"},{"rate":"<0.1","effect":"Rhabdomyolysis (rare)"},{"rate":"1-2","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL393220","moleculeType":"Small molecule","molecularWeight":"1155.36"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Atorvastatin competitively inhibits 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, a key enzyme in the mevalonate pathway responsible for de novo cholesterol synthesis in the liver. This inhibition leads to decreased intracellular cholesterol levels, upregulation of LDL receptors on hepatocytes, and increased clearance of LDL cholesterol from the bloodstream. The net result is a significant reduction in serum LDL cholesterol and triglycerides, with modest increases in HDL cholesterol.","oneSentence":"Atorvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:42:11.987Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia and dyslipidemia"},{"name":"Primary prevention of cardiovascular disease in at-risk patients"},{"name":"Secondary prevention of cardiovascular events in patients with established coronary artery disease"}]},"trialDetails":[{"nctId":"NCT06308952","phase":"PHASE4","title":"Atorvastatin Pretreatment in Cerebrovascular Events (APICES) After Flow Diverter Implantation","status":"RECRUITING","sponsor":"Duan Chuanzhi","startDate":"2024-07-30","conditions":"Cerebrovascular Event, Stent Stenosis, Ischemic Stroke","enrollment":354},{"nctId":"NCT06750783","phase":"PHASE4","title":"The Effects of Xuezhikang and Atorvastatin on Lipid in Patients With Dyslipidemia and Prediabetes","status":"RECRUITING","sponsor":"Beijing Tsinghua Chang Gung Hospital","startDate":"2024-12-31","conditions":"Prediabetic State (IGT)","enrollment":398},{"nctId":"NCT03753555","phase":"PHASE4","title":"The Effect of InTensive Statin in Ischemic Stroke With inTracranial Atherosclerotic Plaques","status":"RECRUITING","sponsor":"General Hospital of Shenyang Military Region","startDate":"2018-12-01","conditions":"Stroke, Ischemic, Atherosclerosis, Cerebral","enrollment":100},{"nctId":"NCT03872388","phase":"PHASE2","title":"Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-09-23","conditions":"Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8","enrollment":6},{"nctId":"NCT03768427","phase":"PHASE3","title":"Ezetimibe (EZ)/Atorvastatin (Ator) (MK-0653C) vs. Ator in Chinese Hypercholesterolemic Participants (MK-0653C-439)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2019-05-27","conditions":"Hypercholesterolemia","enrollment":454},{"nctId":"NCT00276458","phase":"PHASE3","title":"To Evaluate Ezetimibe Plus Atorvastatin Versus Atorvastatin in Patients With High Cholesterol Not Controlled on Atorvastatin 20 mg (0653-079)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-02","conditions":"Hypercholesterolemia","enrollment":196},{"nctId":"NCT04968509","phase":"PHASE3","title":"Effect of PCSK9 Inhibitors on Calcific Aortic Valve Stenosis","status":"RECRUITING","sponsor":"Beijing Anzhen Hospital","startDate":"2024-03-22","conditions":"Aortic Stenosis","enrollment":160},{"nctId":"NCT06112028","phase":"PHASE4","title":"Clinical Study of Tongxinluo Capsule in Preventing and Treating Restenosis After Intracranial and External Arterial Stenting","status":"NOT_YET_RECRUITING","sponsor":"Yanbin Li","startDate":"2023-10","conditions":"Stent Restenosis","enrollment":200},{"nctId":"NCT06096909","phase":"NA","title":"Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese Population","status":"NOT_YET_RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2023-11-01","conditions":"Acute Coronary Syndrome, Non ST Segment Elevation Acute Coronary Syndrome","enrollment":3684},{"nctId":"NCT05976893","phase":"PHASE4","title":"Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and Cancer","status":"UNKNOWN","sponsor":"Xiang Xie","startDate":"2023-08-01","conditions":"ASCVD, Atherosclerotic Cardiovascular Disease, Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor","enrollment":620},{"nctId":"NCT05870007","phase":"PHASE2","title":"Atorvastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney Disease","status":"ENROLLING_BY_INVITATION","sponsor":"Taipei Medical University Shuang Ho Hospital","startDate":"2023-05","conditions":"Autosomal Dominant Polycystic Kidney Disease, Chronic Kidney Diseases","enrollment":30},{"nctId":"NCT03951207","phase":"PHASE4","title":"Rosuvastatin/Amlodipine vs Atorvastatin/Amlodipine in Hypertension Patient With Dyslipidemia","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2019-05-30","conditions":"Dyslipidemias, Hypertension","enrollment":259},{"nctId":"NCT03709355","phase":"PHASE1","title":"Pharmacokinetics Study to Evaluate Drug-Drug Interactions and Safety of Elpida® in Co-Administration With Other Drugs","status":"COMPLETED","sponsor":"Viriom","startDate":"2018-11-14","conditions":"HIV-1-infection","enrollment":56},{"nctId":"NCT03692754","phase":"PHASE2, PHASE3","title":"Atorvastatin in Management of Newly Diagnosed ITP","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2021-11-01","conditions":"Immune Thrombocytopenia, Purpura, Thrombocytopenic","enrollment":30},{"nctId":"NCT04661709","phase":"PHASE4","title":"Efficacy and Safety of Wen Xin Granules for the Treatment of Unstable Angina Pectoris","status":"UNKNOWN","sponsor":"Guang'anmen Hospital of China Academy of Chinese Medical Sciences","startDate":"2021-03-01","conditions":"Coronary Heart Disease, Unstable Angina, Chinese Herbal Medicine","enrollment":502},{"nctId":"NCT01341730","phase":"PHASE4","title":"The Effect of Atorvastatin and Pioglitazone on Carotid Atherosclerosis With the Use of Positron Emission Tomography-computed Tomography (PET-CT)","status":"TERMINATED","sponsor":"The Catholic University of Korea","startDate":"2011-06","conditions":"Atherosclerosis, Coronary Artery Disease","enrollment":41},{"nctId":"NCT03079115","phase":"PHASE4","title":"High Dose Atorvastatin for Preventing Periprocedural Ischemic Brain Damage During Carotid Artery Stenting","status":"UNKNOWN","sponsor":"Beijing Hospital","startDate":"2017-08-21","conditions":"Carotid Artery Stenosis","enrollment":130},{"nctId":"NCT01686230","phase":"NA","title":"Acupuncture in Patients With Stable Angina Pectoris","status":"COMPLETED","sponsor":"Chengdu University of Traditional Chinese Medicine","startDate":"2012-07","conditions":"Angina, Stable","enrollment":404},{"nctId":"NCT02029118","phase":"EARLY_PHASE1","title":"Acupoint Application in Patients With Stable Angina Pectoris (AASAP)","status":"COMPLETED","sponsor":"Chengdu University of Traditional Chinese Medicine","startDate":"2012-10","conditions":"Stable Angina Pectoris","enrollment":200},{"nctId":"NCT03482180","phase":"PHASE3","title":"Evaluate the Efficacy and Safety of KI1106 in Patients Whose TG Level is Not Adequately Controlled With Atorvastatin Calcium Monotherapy While LDL-C is Properly Controlled","status":"COMPLETED","sponsor":"Kuhnil Pharmaceutical Co., Ltd.","startDate":"2016-05-04","conditions":"Dyslipidemias","enrollment":215},{"nctId":"NCT02977065","phase":"PHASE2","title":"To Assess the Safety, Efficacy and Tolerability of CKD-519, Administered With HMG-CoA Reductase Inhibitors","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2017-03-23","conditions":"Dyslipidemias","enrollment":62},{"nctId":"NCT02633956","phase":"PHASE2","title":"Combination Obeticholic Acid (OCA) and Statins for Monitoring of Lipids (CONTROL)","status":"COMPLETED","sponsor":"Intercept Pharmaceuticals","startDate":"2015-12-04","conditions":"Nonalcoholic Steatohepatitis","enrollment":84},{"nctId":"NCT03460808","phase":"PHASE1, PHASE2","title":"The Combination of Atorvastatin, Acetylcysteine and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2018-03-10","conditions":"Immune Thrombocytopenia","enrollment":200},{"nctId":"NCT02790528","phase":"PHASE4","title":"Statin Therapy In Patients With Vasospastic Angina","status":"WITHDRAWN","sponsor":"Seung-Jung Park","startDate":"2017-07","conditions":"Angina Pectoris, Variant, Statins, HMG-CoA","enrollment":""},{"nctId":"NCT01720719","phase":"PHASE4","title":"Atorvastatin Versus Vitamin E in Treatment of Non-alcoholic Fatty Liver Disease","status":"UNKNOWN","sponsor":"Xin Gao","startDate":"2013-05","conditions":"Fatty Liver, Dyslipidemias, Diabetes Mellitus","enrollment":120},{"nctId":"NCT01518231","phase":"PHASE1","title":"Autologous Hematopoietic Stem Cell Transplantation in Ischemic Stroke","status":"UNKNOWN","sponsor":"Zhejiang Hospital","startDate":"2012-01","conditions":"Stroke","enrollment":40},{"nctId":"NCT00770575","phase":"PHASE2","title":"Efficacy Study of Pioglitazone and Atorvastatin Combination Therapy in Treating Subjects With Elevated Risk for Cardiovascular Disease","status":"COMPLETED","sponsor":"Takeda","startDate":"2005-06","conditions":"Cardiovascular Diseases","enrollment":148}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Atorvastatin Calcium 20mg, QD","genericName":"Atorvastatin Calcium 20mg, QD","companyName":"Kuhnil Pharmaceutical Co., Ltd.","companyId":"kuhnil-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Atorvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels. Used for Hypercholesterolemia and dyslipidemia, Primary prevention of cardiovascular disease in at-risk patients, Secondary prevention of cardiovascular events in patients with established coronary artery disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}